The amelioration of streptozotocin diabetes-induced renal damage by Wu-Ling-San (Hoelen Five Herb Formula), a traditional Chinese prescription

Journal of Ethnopharmacology

Volumn 124, Issue 2, 2009, Pages 211-218

  Liu, I Min ^a   Tzeng, Thing Fong ^b   Liou, Shorong Shii ^a   Chang, Chia Ju ^a  

^a TAJEN UNIVERSITY   (Taiwan)

^b Pao Chien Hospital   (Taiwan)

Author keywords

Diabetic nephropathy; STZ diabetic rats; Wu Ling San

Indexed keywords

6 N CARBOXYMETHYLLYSINE; ADVANCED GLYCATION END PRODUCT; ALBUMIN; ALISMATIS EXTRACT; ATRACTYLODES EXTRACT; CHINESE DRUG; CINNAMOMUM CASSIA EXTRACT; FIBRONECTIN; GLUCOSE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PLANT EXTRACT; PORIA COCOS EXTRACT; SCLEROTIUM POLYPORI EXTRACT; THIOBARBITURIC ACID REACTIVE SUBSTANCE; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; WU LING SAN;

ALISMATACEAE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CINNAMOMUM CASSIA; CONTROLLED STUDY; CREATININE CLEARANCE; DIABETIC NEPHROPATHY; DRUG MECHANISM; GLUCOSE BLOOD LEVEL; MALE; MEDICINAL PLANT; MESANGIUM; NONHUMAN; PROTEIN EXPRESSION; RAT; SCLEROTIUM POLYPORI; STREPTOZOCIN DIABETES; URINE LEVEL;

ALBUMINURIA; ANGIOSPERMS; ANIMALS; BLOOD GLUCOSE; CREATININE; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; DRUGS, CHINESE HERBAL; FIBRONECTINS; GLYCOSYLATION END PRODUCTS, ADVANCED; HYPOGLYCEMIC AGENTS; KIDNEY; LYSINE; MALE; MITOCHONDRIA; NF-KAPPA B; PHYTOTHERAPY; PLANT EXTRACTS; RATS; RATS, WISTAR; RECEPTORS, IMMUNOLOGIC; THIOBARBITURIC ACID REACTIVE SUBSTANCES; TRANSFORMING GROWTH FACTOR BETA1;

PORIA COCOS; RATTUS;

EID: 67449149678     PISSN: 03788741     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jep.2009.04.021     Document Type: Article

References (30)

1. Anderson R.A., Broadhurst C.L., Polansky M.M., Schmidt W.F., Khan A., Flanagan V.P., Schoene N.W., and Graves D.J. Isolation and characterization of polyphenol type-A polymers from cinnamon with insulin-like biological activity. Journal of Agricultural and Food Chemistry 52 (2004) 65-70
2. Bakris G.L. The importance of blood pressure control in the patient with diabetes. The American Journal of Chinese Medicine 116 (2004) 30S-38S
3. Border W.A., Okuda S., Languino L.R., Sporn M.B., and Ruoslahti E. Suppression of experimental glomerulonephritis by antiserum against transforming growth factor beta 1. Nature 346 (1990) 371-374
4. Chappey O., Dosquet C., Wautier M.P., and Wautier J.L. Advanced glycation end products, oxidant stress and vascular lesions. European Journal of Clinical Investigation 27 (1997) 97-108
5. Chen D.A. Treating 27 cases of edema in the lower limbs with Wu Ling San. Journal of Traditional Chinese Medicine 16 (1998) 19-20
6. Dominguez J.H., Tang N., Xu W., Evan A.P., Siakotos A.N., Agarwal R., Walsh J., Deeg M., Pratt J.H., March K.L., Monnier V.M., Weiss M.F., Baynes J.W., and Peterson R. Studies of renal injury β: lipid-induced nephropathy in type α diabetes. Kidney International 57 (2000) 92
7. Falk R.J., Scheinman J.I., Mauer S.M., and Michael A.F. Polyantigenic expansion of basement membrane constituents in diabetic nephropathy. Diabetes 32 (1983) 34-39
8. Fu M.X., Requena J.R., Jenkins A.J., Lyons T.J., Baynes J.W., and Thorpe S.R. The advanced glycation end product, Nepsilon-(carboxymethyl)lysine, is a product of both lipid peroxidation and glycoxidation reactions. The Journal of Biological Chemistry 271 (1996) 9982-9986
9. Gross M.L., Heiss N., Weckbach M., Hansen A., El-Shakmak A., Szabo A., Münter K., Ritz E., and Amann K. ACE-inhibitors but not endothelin receptor blockers prevent podocyte loss in early diabetic nephropathy. Diabetologia 46 (2003) 856-868
10. Guangdong Medical Journal Editorial Department. Clinical observation of curative effects of Wu Ling San for treatment of glaucoma. Guangdong Medical Journal 3 (1982) 40
11. Hattori T., Fujitsuka N., Kurogi A., and Shindo S. Sairei-to may inhibit the synthesis of endothelin-1 in nephritic glomeruli. Nippon Jinzo Gakkai Shi 39 (1997) 121-128
12. He L., Rong X., Jiang J.M., Liu P.Q., and Li Y. Amelioration of anti-cancer agent adriamycin-induced nephrotic syndrome in rats by Wulingsan (Gorei-San), a blended traditional Chinese herbal medicine. Food and Chemical Toxicology 46 (2008) 1452-1460
13. Hodge H.C., Downs W.L., Panner B.S., Smith D.W., and Maynard E.A. Oral toxicity and metabolism of diuron (N-(3,4-dichlorophenyl)-N′N′-dimethylurea) in rats and dogs. Food and Cosmetics Toxicology 5 (1967) 513-531
14. Janero D.R., and Burghardt B. Analysis of cardiac membrane phospholipid peroxidation kinetics as malondialdehyde: nonspecificity of thiobarbituric acid-reactivity. Lipids 23 (1988) 452-458
15. Janiak P., Bidouard J.P., Cadrouvele C., Poirier B., Gouraud L., Grataloup Y., Pierre F., Bruneval P., O'Connor S.E., and Herbert J.M. Long-term blockade of angiotensin AT1 receptors increases survival of obese Zucker rats. European Journal of Pharmacology 534 (2006) 271-279
16. Jung K., and Pergande M. Influence of cyclosporin A on the respiration of isolated rat kidney mitochondria. FEBS Letters 183 (1985) 167-169
17. Kalantarinia K., and Okusa M.D. The renin-angiotensin system and its blockade in diabetic renal and cardiovascular disease. Current Diabetes Reports 6 (2006) 8-16
18. Kanwar Y.S., Wada J., Sun L., Xie P., Wallner E.I., Chen S., Chugh S., and Danesh F.R. Diabetic nephropathy: mechanisms of renal disease progression. Experimental Biology and Medicine 233 (2008) 4-11
19. Koya D., Hayashi K., Kitada M., Kashiwagi A., Kikkawa R., and Haneda M. Effects of antioxidants in diabetes-induced oxidative stress in the glomeruli of diabetic rats. Journal of the American Society of Nephrology 14 (2003) 250S-253S
20. Liu Q.L., Sato S., Kishikawa T., Matsuzaki H., and Yamanaka N. Effectiveness of a traditional Chinese medicine, Wulingsan, in suppressing the development of nephrocalcinosis induced by a high phosphorus diet in young rats. Medical Electron Microscopy 34 (2001) 103-114
21. Nakayama H., Mitsuhashi T., Kuwajima S., Aoki S., Kuroda Y., Itoh T., and Nakagawa S. Immunochemical detection of advanced glycation end products in lens crystallins from streptozocin-induced diabetic rat. Diabetes 42 (1993) 345-350
22. Parving H.H., Lehnert H., Brochner-Mortensen J., Gomis R., Andersen S., and Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. The New England Journal of Medicine 345 (2001) 870-878
23. Peng X., Cheng K.W., Ma J., Chen B., Ho C.T., Lo C., Chen F., and Wang M. Cinnamon bark proanthocyanidins as reactive carbonyl scavengers to prevent the formation of advanced glycation endproducts. Journal of Agricultural and Food Chemistry 56 (2008) 1907-1911
24. Prabhakar S., Starnes J., Shi S., Lonis B., and Tran R. Diabetic nephropathy is associated with oxidative stress and decreased renal nitric oxide production. Journal of the American Society of Nephrology 18 (2007) 2945-2952
25. Rossing P. Diabetic nephropathy: worldwide epidemic and effects of current treatment on natural history. Current Diabetes Reports 6 (2006) 479-483
26. Schrijvers B.F., and De Vriese A.S. Novel insights in the treatment of diabetic nephropathy. Acta Clinica Belgica 62 (2007) 278-290
27. Vasavada N., and Agarwal R. Role of oxidative stress in diabetic nephropathy. Advances in Chronic Kidney Disease 12 (2005) 146-154
28. Viberti G., and Wheeldon N.M. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 106 (2002) 672-678
29. Yamagishi S., Fukami K., Ueda S., and Okuda S. Molecular mechanisms of diabetic nephropathy and its therapeutic intervention. Current Drug Targets 8 (2007) 952-959
30. Yoshimura K., Miyake O., Okuyama A., Yoshioka T., Honda M., Yamaguchi S., and Koide T. Effect of chorei-to and gorei-san on calcium oxalate crystallization in human urine. Acta Urologica Japonica 44 (1998) 13-16